Potentials for the correction of endothelial and erectile dysfunction in patients after coronary artery bypass. surgery


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to the evaluation the effect of NO- synthase inducer impaza on endothelial function and erectile function in patients undergoing coronary artery bypass grafting (CABG). The study involved 127 men with stable coronary artery disease (CAD), aged 55,8±5,3 years, which were planned on CABG. The survey included assessment of IIEF score and blood lipid levels, registration of nocturnal penile tumescences, postcompression tests on the shoulder and cavernous arteries. Endothelial function was assessed as the plasma levels of nitric oxide (NO) and endothelin-1 (ET-1). The comparison group of patients (n=67) were treated with standard rehabilitation program, and the study group (n=67) additionally has received impaza 1 tablet a day for 24 weeks. It is shown that in patients with erectile dysfunction (ED) undergoing CABG, the use of impaza for 24 weeks facilitates optimal dynamic expression of the ED. But a year after the operation, there were marked deterioration in erectile function, indicating a short-term effect of action of impaza that may require its longer use. In addition, 6 months after CABG, patients receiving impaza had better indicators of functional activity of the endothelium in shoulder and cavernous arteries compared with patients who received conventional rehabilitation; one year after surgery, however, there were no significant differences in these parameters. Restorative treatment using impaza in CAD patients after myocardial revascularization operations has positive influence on the NO, ET-1 levels, which is reflected in the functional state of the endothelium and characterized by an increase in vasodilator properties and decrease in vasoconstrictor properties.

Full Text

Restricted Access

References

  1. Nia F., Abdollahi S.K., Hassan M. Hekmatimoghaddam et al. Incidence of sexual dysfunction in men after cardiac surgery in Afshar hospital, Yazd. Iranian Journal of Reproductive Medicine. 2011; 9(2): 89-94.
  2. Shaw J., Walker S.F. Coronary heart disease strategies to reduce risk factors. Curr Ther. 1991; 31: 23-303.
  3. Panagiotopoulos I., Palatianos G., Michalopoulos A. et al. Alterations in biomarkers of endothelial function following on-pump coronary artery revascularization. J Clin. Lab. Anal. 2010; 24(6):389—398.
  4. La Vignera S., Condorelli R., Vicari E. et al. Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction. J. Endocrinol. Invest. 2011; 34(10): 314—320.
  5. Dong J.Y., Zhang Y.H., Qin L.Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol. 2011;58(13):1378—1385.
  6. Карпов Ю.А., Самко А.Н., Буза В.В. Медикаментозное и инвазивное лечение стабильной ИБС: как сделать правильный выбор? Кардиол. вестн. 2009; 2(4): 5—11.
  7. Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия 2009. Болезни и врожденные аномалии системы кровообращения. М.: НЦССХ им. А. Н. Бакулева РАМН, 2010. 180 с.
  8. Dirk P.J. Michielsen, Jean Jacques Amy. Nocturnal electrobioimpedance volumetric Assessment (NEVA®): an alternative for determining the quality of nocturnal erections. Arch Med Sci. 2005 ; 1(2):110—114.
  9. Mazo E., Gamidov S., Andranovich S. et al. Testing endothelial function of brachial and cavernous arteries in patients with erectile dysfunction. J Sex Med. 2006; 3: 323-330.
  10. Rosen R.C., Cappelleri J.C., Smith M.D. et al. Constructing and evaluating the “Sexual Health Inventory for Men: IIEF-5” as a diagnostic tool for erectile dysfunction (ED). Int. J Impotence Research 1998; 10: S3-S35.
  11. Иванова О.В., Балахонова Т.В., Соболева Г.Н. и др. Состояние эндотелийзависимой вазодилатации плечевой артерии у больных гипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения. Кардиология. 1997; 7: 41-46.
  12. Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х. и др. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. Уральский медицинский журнал. 2012; 3: 75-79.
  13. Хамзин А.А. Особенности эректильной дисфункции при сердечно-сосудистых заболеваниях. Андрология и генитальная хирургия. 2010; 4: 53-56.
  14. Montorsi F., Briganti A., Salania A. et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery. Eur. Urol. 2003;44 (3): 360-364.
  15. Wespes E., Schulman C.C. Erectile dysfunction and cardiovascular diseases. Arch. Esp. Urol. 2010; 63 (8): 649-654.
  16. Hizli F., Işler B., Güneş Z. et al. What is the best predictor of postoperative erectile function in patients who will undergo coronary artery bypass surgery? Int Urol Nephrol. 2007; 39(3): 909-912.
  17. Birkan Akbulut, Halil Ibrahim Uçar, Bahar Öç et al. Erectile function after coronary artery bypass surgery. Anatol J Clin Investig. 2008; 2(4): 146-149.
  18. Chew K.K., Finn J., Stuckey B. et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J. Sex. Med. 2010;7 (1): 192-202.
  19. Камалов А.А., Дорофеев С.Д., Ефремов Е. А. Импаза в лечении эректильной дисфункции. Урология. 2005;5: 27-31.
  20. Князькин И.В., Зезюлин П.Н., Сморчков А.А. и др. Применение препарата импаза в терапии эректильной дисфункции. Урология. 2004; 2:36-37.
  21. Неймарк А.И., Алиев Р.Т., Музалевская Н.И. и др. Использование импазы в лечении эректильной дисфункции у пациентов с гипертонической болезнью и ИБС. Бюллетень экспериментальной биологии и медицины 2009; 8 (приложение): 76-79.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies